Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07448155) titled 'A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous Administration in Healthy Adult Participants' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Incyte Corporation
Condition:
Healthy Participants
Intervention:
Drug: INCA033989
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: March 19, 2026
Target Sample Size: 72
Countries of Recruitment:
United States
To know more, v...